Technical Articles

PD-1 inhibitors and PD-L1 inhibitors, as immune checkpoint inhibitors targeting the same pathway, enhance T cell recognition and killing of tumor cells by blocking the binding of PD-1 to PD-L1, thereby exerting anti-tumor effects.